Status:
ACTIVE_NOT_RECRUITING
ATGAM General Investigation
Lead Sponsor:
Pfizer
Conditions:
Aplastic Anemia
Eligibility:
All Genders
Brief Summary
The objective of this study is to confirm the safety of ATGAM in patients with moderate to severe aplastic anemia under the actual use in Japan. The registration criteria is patients with moderate to...
Eligibility Criteria
Inclusion
- Patients with moderate to severe aplastic anemia who receive ATGAM
Exclusion
- No exclusion criteria is set out in this study.
Key Trial Info
Start Date :
February 21 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 22 2027
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT06039020
Start Date
February 21 2024
End Date
January 22 2027
Last Update
November 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer
Tokyo, Japan